Tekturna question

Quote

Anonymous

Guest
I dont get it !

A DRI provides more comprehensive control of an overactive RAAS in a diabetic patient. And I understand that minimizing Ang 1 and Ang ll is a good thing but what exactly is the benefit here. BP drop is similar to an ACE or ARB. The renal protection benefit is off label.

Can someone offer more insight ?
 












Anonymous said:
I dont get it !

A DRI provides more comprehensive control of an overactive RAAS in a diabetic patient. And I understand that minimizing Ang 1 and Ang ll is a good thing but what exactly is the benefit here. BP drop is similar to an ACE or ARB. The renal protection benefit is off label.

Can someone offer more insight ?
Click to expand...

it's a marketing SCAM that's all . tekturkey was covered in their previous lawsuit so
they think they have free reign to sell off lable since they've already paid a fine on
it & other CV drugzzzz
 






I get the mech. of action and the theory that more complete blockage of the RAAS should be agood thing, but those are all features of the drug. What are the potential benefits ?
 






Anonymous said:
I get the mech. of action and the theory that more complete blockage of the RAAS should be agood thing, but those are all features of the drug. What are the potential benefits ?
Click to expand...

why would one talk so much about the mechanism and say nothing about the proven benefit? Maybe there is nothing to say?
 












no really. what is the clinical implication ? is there data that states increased plasma renin activity with ACE and ARB's has a negative clinical impact ? tekturna shows a decreased PRA across the board, but what does that mean to a physician and what does it mean to a patient ?
 


















if the patient is a high renin patient tekturna is a great drug and will work better than an ACE or ARB. ACE and ARB are unable to inhibit renin when the PRA is high. The problem is trying to figure out who these pt are. Insurance comp. want pt on ACE and ARB first either way. Bottom line, if a pt is not responding to an ACE or Losartan get them on Tekturna, the phys. may be pleasantly surprised.
 






I never quite bought-in to the DRI story. I understand RAA system quite well, and how a DRI works. However, here's the rub. With an ARB you get good drops in BP, even though there is a compensatory increase in plasma renin levels. Why, because you get blockage of the angiotensin receptors with an ARB, so it doesn't matter how much circulating renin you have; you still get a drop in BP. With an ACEI, you may not have the same effect, since the renin is already triggered and the ACEI lowers BP by inhibiting the RAA system to produce ANG2. Here the DRI may be a factor. From the physician's perspective, does DRI mean anything? Probably not. Clinically, there does not seem to be a difference. Recall DOEs and POEMs. A DOE is Disease Oriented Evidence: that's what the DRI story is all about. But POEMs are Patient Oriented Evidence that Matters, both clinically to the doc and quality of life evidence to the Patient. I don't think the DRI is a POEM.
 






Anonymous said:
no really. what is the clinical implication ? is there data that states increased plasma renin activity with ACE and ARB's has a negative clinical impact ? tekturna shows a decreased PRA across the board, but what does that mean to a physician and what does it mean to a patient ?
Click to expand...

PRA is a mechanism in the body which is designed to RAISE blood pressure. Every time BP is lowered, for ANY and EVERY reason, PRA is there to raise it back again. So the point is, if you agree that lowering BP is a good thing to help get people to goal and to live long healthy lives, then how can you ignore PRA? Tekturna is not the answer in and of itself, but probably no other med. alone is either.... if physicians are serious about longterm goal achievement for their patients and sustaining them there, they must feel compelled to use Tekturna somewhere in there algorithm... earlier rather than later. Otherwise patients will ALWAYS have an overactive mechanism (PRA) which is trying to counteract every goal the physician is trying to achieve with the patient.
Makes perfect sense to me...
 






So funny that you all are probably giving the competitor info! I could care less as well....the part about the high renin driven patient = true. That's the only niche this drug has, but difficult to tell who those patients are.
 






Anonymous said:
PRA is a mechanism in the body which is designed to RAISE blood pressure. ...
Click to expand...

Too many drugs that acting on the raas have negative consequences. Your marketing PR spin is pure BS. The efficacy of tekturkey is negligable . Barely above a placebo. No proven outcomes. Do society a favor & tell your docs generic vasotec or norvasc can do 2-3x a better job at lowering BP for pennies on the $$$ much to the chagrin of novartis & their sinking CV portfolio
 












Anonymous said:
So funny that you all are probably giving the competitor info! I could care less as well....the part about the high renin driven patient = true. That's the only niche this drug has, but difficult to tell who those patients are.
Click to expand...

Clearly you don't understand hypertension.... High PRA on a drug-naive patient is in the 70% range. Once you treat that patient's hypertension with any med., that percentage goes to 100%. By treating the patient and lowering their BP, you have caused that patient to have high PRA. regardless if they were high PRA prior to treatment or not. So how is 100% a niche?
 






Anonymous said:
Clearly you don't understand hypertension.... High PRA on a drug-naive patient is in the 70% range. Once you treat that patient's hypertension with any med., that percentage goes to 100%. By treating the patient and lowering their BP, you have caused that patient to have high PRA. regardless if they were high PRA prior to treatment or not. So how is 100% a niche?
Click to expand...

You're a r*****. Tekturkey PRA = the 2011 version of Starlix IGT
Dubious science to say the least.
How's that navigator trial working out for you ??
 












Top Bottom
Back
Quote